TYK2 Inhibitors Show Efficacy in Psoriatic Arthritis - Medpage Today

Описание к видео TYK2 Inhibitors Show Efficacy in Psoriatic Arthritis - Medpage Today

At the American College of Rheumatology (ACR) virtual meeting, promising results were announced from two studies evaluating the efficacy of brepocitinib, an oral tyrosine kinase 2 (TYK2)/Janus kinase 1 (JAK1) inhibitor, and deucravacitinib, an oral TYK2 inhibitor, compared with placebo in patients with active psoriatic arthritis.

In this second of four exclusive episodes, MedPage Today brought together three expert leaders in the field, all from the Cleveland Clinic -- moderator M. Elaine Husni, MD, MPH, is joined by Leonard Calabrese, DO, and Anthony Fernandez, MD, PhD -- for a virtual roundtable discussion about the results of these studies.

Комментарии

Информация по комментариям в разработке

Похожие видео